Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Appointment of CFO and Resignation of Interim FO

Ceo ResignedCfo ResignedKmp ResignedManagement Changes View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹379.20

prior close

₹370.40

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-2.2%+0.1% vs market

Pharmaceuticals peers, median of 155sector-2.9%+0.8% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.4

15m

+0.4

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1-2.2+0.1-2.9+0.8

Next day

-5.1-4.7-0.3-4.7-0.3

-3.9-2.6-1.3-1.1-2.7

-7.2-2.9-4.3-0.7-6.5

-6.3-1.5-4.8+0.8-7.2

-10.3-1.4-8.9+1.4-11.7

-9.0+2.8-11.8+5.0-14.0

15d

-5.6+8.8-14.4+9.3-14.9

-4.6+8.8-13.4+10.8-15.4

+14.4+12.2+2.2+15.6-1.2

+9.2+11.2-2.0+18.4-9.2

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon's board, at its meeting on March 27, 2026, approved major leadership changes effective April 1, 2026, linked to the ongoing integration of Biocon Biologics with Biocon Limited. CEO & Managing Director Siddharth Mittal resigned effective March 31, 2026 to take up another role within the Biocon Group. He will be replaced by Shreehas Tambe, currently CEO & MD of Biocon Biologics, who will serve as CEO & MD for a 5-year term. Interim CFO Mukesh Kamath also stepped down effective March 31, 2026, with Kedar Upadhye, current CFO of Biocon Biologics, appointed as the new CFO. Additionally, 7 senior management personnel (including the CCO, CSO, COO, and Head of HR) ceased their roles, while new leaders from Biocon Biologics were designated as KMPs and senior management at Biocon Limited.

Likely market impact

The leadership overhaul signals the merger integration with Biocon Biologics is moving forward, with experienced internal Group leaders taking the top roles to ensure continuity. Investors may find this reassuring for execution, though the sweeping senior management changes could create short-term transition risk.